Next-Gen CAR T & Novel SMA Drug Among New Entrants On EMA’s PRIME
Rare Pediatric Disease Drug & Multiple Myeloma Therapy Also Make The Grade
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.
